Usefulness and optimization of mouse models of allergic airway disease

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 3, 2008, Pages 603-606

  Finkelman, Fred D ^a,b,c   Wills Karp, Marsha ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ALLERGIC DISEASE; ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; LIVER FUNCTION; LOW DRUG DOSE; LUNG FUNCTION TEST; MEDICAL RESEARCH; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TREATMENT FAILURE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY; MICE;

EID: 40049106971     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.01.008     Document Type: Editorial

References (37)

1. Wenzel S., and Holgate S.T. The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med 174 (2006) 1173-1176
2. Shapiro S.D. Animal models of asthma: Pro: allergic avoidance of animal (model[s]) is not an option. Am J Respir Crit Care Med 174 (2006) 1171-1173
3. Kips J.C., Anderson G.P., Fredberg J.J., Herz U., Inman M.D., Jordana M., et al. Murine models of asthma. Eur Respir J 22 (2003) 374-382
4. Coleman R. Current animal models are not predictive for clinical asthma. Pulm Pharmacol Ther 12 (1999) 87-89
5. Gelfand E.W. Pro: mice are a good model of human airway disease. Am J Respir Crit Care Med 166 (2002) 5-6
6. Persson C.G. Con: mice are not a good model of human airway disease. Am J Respir Crit Care Med 166 (2002) 6-7
7. Corry D.B., and Irvin C.G. Promise and pitfalls in animal-based asthma research: building a better mousetrap. Immunol Res 35 (2006) 279-294
8. Canning B.J. Modeling asthma and COPD in animals: a pointless exercise?. Curr Opin Pharmacol 3 (2003) 244-250
9. Taube C., Dakhama A., and Gelfand E.W. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 135 (2004) 173-186
10. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int Arch Allergy Immunol 133 (2004) 84-100
11. Pabst R. Animal models for asthma: controversial aspects and unsolved problems. Pathobiology 70 (2002) 252-254
12. Lewkowich I.P., and Wills-Karp M. Animal models of allergen-induced asthma. In: Adkinson N.F., Busse W.W., Bochner B.S., Holgate S.T., Simons F.E., and Lemanske R.F.J. (Eds). Middleton's allergy: principles and practice. 7th ed. (2008), Elsevier, London In press
13. Guenet J.L. The mouse genome. Genome Res 15 (2005) 1729-1740
14. Kumar R.K., and Foster P.S. Murine model of chronic human asthma. Immunol Cell Biol 79 (2001) 141-144
15. Henderson Jr. W.R., Lu J., Poole K.M., Dietsch G.N., and Chi E.Y. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J Immunol 164 (2000) 3360-3367
16. Leonard P., and Sur S. Interleukin-12: potential role in asthma therapy. BioDrugs 17 (2003) 1-7
17. Gomez F.P., and Rodriguez-Roisin R. Platelet-activating factor antagonists: current status in asthma. BioDrugs 14 (2000) 21-30
18. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., et al. Interleukin-13: central mediator of allergic asthma. Science 282 (1998) 2258-2261
19. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., and Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183 (1996) 195-201
20. Corry D.B., Folkesson H.G., Warnock M.L., Erle D.J., Matthay M.A., Wiener-Kronish J.P., et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 183 (1996) 109-117
21. Sato T.A., Widmer M.B., Finkelman F.D., Madani H., Jacobs C.A., Grabstein K.H., et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150 (1993) 2717-2723
22. Riffo-Vasquez Y., and Spina D. Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. Pharmacol Ther 94 (2002) 185-211
23. Hozawa S., Haruta Y., Ishioka S., and Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 152 (1995) 1198-1202
24. Gavett S.H., O'Hearn D.J., Li X., Huang S.K., Finkelman F.D., and Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 182 (1995) 1527-1536
25. Bryan S.A., O'Connor B.J., Matti S., Leckie M.J., Kanabar V., Khan J., et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2149-2153
26. Milgrom H., Fick Jr. R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 341 (1999) 1966-1973
27. Grunig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998) 2261-2263
28. Corren J., Casale T., Deniz Y., and Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 111 (2003) 87-90
29. Finn A., Gross G., van Bavel J., Lee T., Windom H., Everhard F., et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111 (2003) 278-284
30. Karras J.G., Crosby J.R., Guha M., Tung D., Miller D.A., Gaarde W.A., et al. Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice. Am J Respir Cell Mol Biol 36 (2007) 276-285
31. Gavett S.H., O'Hearn D.J., Karp C.L., Patel E.A., Schofield B.H., Finkelman F.D., et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol Lung Cell Mol Physiol 272 (1997) L253-L261
32. Wenzel S., Wilbraham D., Fuller R., Getz E.B., and Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370 (2007) 1422-1431
33. Rothenberg M.E., Gleich G.J., Roufosse F.E., Rosenwasser L.J., and Weller P.F. Steroid-sparing effects of anti-IL-5 monoclonal antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood 108 (2006) 115a
34. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 (2006) 1312-1319
35. Plotz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
36. Gevaert P., Lang-Loidolt D., Lackner A., Stammberger H., Staudinger H., Van Zele T., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118 (2006) 1133-1141
37. Finkelman F.D. Use of unrestrained, single-chamber barometric plethysmography to evaluate sensitivity to cholinergic stimulation in mouse models of allergic airway disease. J Allergy Clin Immunol 121 (2008) 334-335